Bratton Capital Management L.P. Takes Position in Aquestive Therapeutics, Inc. $AQST

Bratton Capital Management L.P. bought a new stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 9,810,958 shares of the company's stock, valued at approximately $40,813,585. Aquestive Therapeutics makes up 0.1% of Bratton Capital Management L.P.'s holdings, making the stock its largest position. Bratton Capital Management L.P. owned 7.82% of Aquestive Therapeutics at the end of the most recent reporting period.

Several other large investors have also modified their holdings of AQST. AQR Capital Management LLC boosted its holdings in shares of Aquestive Therapeutics by 12.2% in the 1st quarter. AQR Capital Management LLC now owns 129,019 shares of the company's stock valued at $374,000 after buying an additional 14,025 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Aquestive Therapeutics by 16.2% in the 2nd quarter. Geode Capital Management LLC now owns 1,977,001 shares of the company's stock valued at $6,545,000 after buying an additional 276,295 shares in the last quarter. Creative Planning boosted its holdings in shares of Aquestive Therapeutics by 15.3% in the 2nd quarter. Creative Planning now owns 98,751 shares of the company's stock valued at $327,000 after buying an additional 13,130 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Aquestive Therapeutics by 46.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 435,972 shares of the company's stock valued at $1,443,000 after buying an additional 137,956 shares in the last quarter. Finally, Rhumbline Advisers boosted its holdings in shares of Aquestive Therapeutics by 35.0% in the 2nd quarter. Rhumbline Advisers now owns 140,872 shares of the company's stock valued at $466,000 after buying an additional 36,509 shares in the last quarter. Institutional investors and hedge funds own 32.45% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on AQST. Weiss Ratings restated a "sell (d-)" rating on shares of Aquestive Therapeutics in a report on Friday, July 17th. HC Wainwright restated a "buy" rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a report on Monday, August 24th. Finally, Wall Street Zen cut shares of Aquestive Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, August 15th. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Aquestive Therapeutics has an average rating of "Buy" and an average price target of $8.80.

Aquestive Therapeutics Price Performance

Shares of NASDAQ:AQST opened at $5.02 on Friday. The stock has a market cap of $630.06 million, a P/E ratio of -7.72 and a beta of 1.49. The firm has a fifty day moving average price of $4.24 and a 200 day moving average price of $4.16. Aquestive Therapeutics, Inc. has a 1-year low of $2.93 and a 1-year high of $7.55.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.08). The company had revenue of $13.82 million for the quarter, compared to analysts' expectations of $11.42 million. Sell-side analysts expect that Aquestive Therapeutics, Inc. will post -0.5 EPS for the current fiscal year.

Insider Buying and Selling

In other Aquestive Therapeutics news, Director Julie Krop sold 25,000 shares of the company's stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $5.02, for a total transaction of $125,500.00. Following the completion of the transaction, the director owned 25,000 shares in the company, valued at approximately $125,500. This represents a 50.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.81% of the company's stock.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company's lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.